Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,430 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Healthy Subjects
Interventions: fosamprenavir + ritonavir + methadone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 2
States / cities: Baltimore, Maryland • Buffalo, New York

Conditions: Otitis Media
Interventions: Intranasal fentanyl, morphine IM, IV morphine; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 6 Months to 6 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Opioid Withdrawal, Opioid Use Disorder (OUD)
Interventions: Sparrow Link (Active tAN), Sparrow Link (Sham tAN); Device
Lead sponsor: Payel Roy; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depression, Major Depressive Disorder
Interventions: Naltrexone 50 Mg Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: Marta Peciña, MD PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Anterior Cruciate Ligament Injuries
Interventions: Opiate Sparing, Opiate Based; Drug
Lead sponsor: Campbell Clinic; Other
Eligibility: 14 Years to 85 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Skokie, Illinois • Cincinnati, Ohio • Memphis, Tennessee

Conditions: Opioid Use Disorder
Interventions: NTX/BUP, NTX/PBO-B, PBO-N/PBO-B; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Oceanside, California • Orange, California • Lauderhill, Florida + 17 more

Conditions: Cocaine Abuse, Cocaine Dependence, Opiate Dependence, Alcohol Dependence, Substance Abuse
Interventions: modafinil, d-amphetamine, L-Dopa, Naltrexone; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Disease, Pain
Interventions: morphine sulfate and naltrexone hydrochloride (EMBEDA); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years and older
Enrollment: 684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 166
States / cities: Adamsville, Alabama • Birmingham, Alabama • Huntsville, Alabama + 144 more

Conditions: Prolonged Grief Disorder
Interventions: Naltrexone HCl 50 MG Oral Tablet, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: Placebo, Buprenorphine 0.15 MG [Belbuca]; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions: Noscapine; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Laparoscopic Surgery
Interventions: Carbon dioxide, Bupivacaine, Oxycodone; Other · Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 19 Years to 41 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2001
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Acute Pain
Interventions: Oxymorphone immediate release; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 21
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 10 more

Conditions: Opioid-Related Disorders
Interventions: buprenorphine hydrochloride; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Pain, Opioid Use
Interventions: Opioid Phase; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Dialectical Behavior Therapy, Individual and Group Drug Counseling
Interventions: DBT, I/GDC; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pain, Post-operative
Interventions: Memantine, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Weight Loss, Pain, Postoperative
Interventions: Topamax, Gabapentin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 0
States / cities: Not listed

Conditions: Opioid Addiction
Interventions: FMRI, Suboxone; Other · Drug
Lead sponsor: Butler Hospital; Other
Eligibility: 21 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Nephrolithiasis, Ureteral Calculi
Interventions: tamsulosin, Standard therapy with ibuprofen and oxycodone.; Drug
Lead sponsor: MaineHealth; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Elbow Fracture
Interventions: Oxycodone with Acetaminophen, Bupivacaine 0.25%, Ropivacaine 0.20%; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 4 Years to 12 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Alcohol Drinking, Opioid Use, Unspecified
Interventions: Naltrexone, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 35 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.

Postoperative Effects of Intranasal Fentanyl, IV and IM Morphine in Children Undergoing Myringotomy

Sparrow Link Neuromodulation Device for Opioid Withdrawal Management in Hospitalized Adults With Opioid Use Disorder

Study of Naltrexone-Induced Blockade of Antidepressant Effects

Reduce Opiate Exposure With ACL Surgery

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

Substance Abuse Pre-Treatment Screening Study

Conversion to Embeda With Rescue Trial

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy

Short Title: Standard vs. Lower Pressure Pneumoperitoneum

Buprenorphine Dose Alteration Study - 1

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions

Neuroimaging of Opioid Phase (OPAL)

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

DBT Compared to I/GDC for the Treatment of Opiate Addiction in Emotionally Dysregulated Patients. - 1

Memantine for Post-Operative Pain Control

Beneficial Side Effects of Topiramate in Obese Patients Undergoing Total Joint Arthroplasty

Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence

The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients

The Post-Operative Pain Management of Pediatric Supracondylar Elbow Fractures

Opioid Modulation and Neural Reward Activation in Healthy Adults